🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being hailed as a "huge turning point" in the effort against superbug strains of the infection, according to health experts.

An International Health Concern

Cases of gonorrhoea are increasing globally, with figures suggesting in excess of 82 million instances per year. Particularly high rates are observed in Africa and countries within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have reached a record high, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune advancement in the context of rising global incidence, increasing antimicrobial resistance and the very limited therapeutic options presently on offer.”

Health officials are deeply concerned about the increase in treatment-resistant strains. The WHO has designated it as a "priority pathogen". Recent surveillance found that the effectiveness of primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Treatment Options Receive Authorization

Zoliflodacin, alternatively called Nuzolvence, was cleared by the US Food and Drug Administration in mid-December for combating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Scientists anticipate that focused deployment of this new drug will help slow the development of resistance.

Another new antibiotic, created by the drugmaker GSK, also received approval in concurrent days. This drug, which is additionally indicated for urinary tract infections, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin emerged from a innovative non-profit model for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to see it through.

“This milestone marks a significant shift in the management of superbug gonorrhoea, which previously has been outpacing our drug pipeline.”

Clinical Trial Results and Worldwide Availability

According to results detailed in a prominent scientific publication, zoliflodacin eradicated the vast majority of cases of the STI. This puts it on an similar efficacy with the typical regimen, which involves an injection and a pill. The study included hundreds of volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the authority to make available and distribute the drug in a wide range of regions with limited resources.

Clinicians on the front lines have shared hope. Access to a easy-to-administer therapy such as this is hailed as a "revolutionary step" for gonorrhoea control. This is considered vital to reduce the burden of the disease for people and to stop the proliferation of highly drug-resistant gonorrhoea globally.